Snapshot

Updates from your followed companies

Roche's Evrysdi tablet approved in EU for spinal muscular atrophy

Roche has received approval from the European Commission for a new tablet formulation of Evrysdi (risdiplam), marking...

Pharmafile

How would you rate Roche's CEO Thomas Schinecker?

I don´t know

Nephrology Drugs Market Is Booming So Rapidly 2025-2032 - Amgen Inc., F. Hoffmann-La Roche Ltd, Sanofi, Novartis AG

Global nephrology drugs market is estimated to be valued at USD 18.37 Bn in 2025 and is expected to reach USD 29.14 B...

Openpr

Recommended Companies Like what you see? Companies in this section will change, so be sure to follow companies that matter to you to receive regular updates. Learn more about following companies

BioNTech and Bristol Myers Squibb collaborate on bispecific antibody for solid tumours

BioNTech and Bristol Myers Squibb (BMS) have entered a partnership to collaboratively develop and commercialise BNT32...

Pharmafile

Pfizer, Arvinas Partnered Breast Cancer Drug Cuts Progression Risk By 43% In Trial, Seeks FDA Approval

Arvinas and Pfizer submit NDA to FDA for vepdegestrant after Phase 3 data shows efficacy in ESR1-mutated ER+/HER2- br...

Benzinga

Johnson & Johnson's Akeega from AMPLITUDE study shows improved efficacy in patients with HRRmutated mHSPC

Johnson & Johnson announced first results from the phase 3, randomised, double─blind, placebo─controlled AMPLITUDE st...

Pharmabiz

Syndeio Biosciences Lands $90M

INDIANAPOLIS, IN, Syndeio Biosciences announced its launch to pioneer precision neurotherapeutics.

VC News Daily

Bayer blockbuster Nubeqa receives US FDA approval for patients with advanced prostate cancer

Bayer announced that the US Food and Drug Administration (FDA) has approved its oral androgen receptor inhibitor (ARi...

Pharmabiz

Tracer Biotechnologies and QIAGEN to advance blood-based MRD testing for solid tumors

Seeking Alpha

Breaking Down Medtronic: 4 Analysts Share Their Views

Benzinga

EU approves AstraZeneca's Calquence in combo with venetoclax, with or without obinutuzumab to treat adult patients with previously untreated CLL

A fixed─duration regimen of AstraZeneca's Calquence (acalabrutinib) in combination with venetoclax, with or without o...

Pharmabiz

AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE

In This Article: THOUSAND OAKS, Calif. , June 5, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) will present at the Goldma...

Yahoo

Procter & Gamble to cut 7,000 jobs as part of broader restructuring

CFO Andre Schulten said more details about the job cuts will be shared on the company's fiscal fourth-quarter earning...

CNBC

Learn more about Owler Plans

Use of Owler products is governed by our Terms of Use and Privacy Policy